Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$38.9M
12M shares
52-week range
$1.98 – $9.99
18% from low
Exchange
XASE
CS
Borrow rate
20.64%
Hard to borrow
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.
www.nasuspharma.comNo one on the platform currently holds NSRX.
No tracked institution reports a position in NSRX as of their last filing.
No one on the platform has traded NSRX yet.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$NSRX Time is ticking fast . Q4/2026 is coming soon . Then this stock will explode massively. Buy and hold tight and be patient. 9-10$ is coming in Q4/2026 .
View on StockTwits ↗Nasus Pharma (NYSE American: $NSRX ) brings its Nasax intranasal drug delivery technology for medical emergencies to the Life Sciences Virtual Investor Forum on June 25 at 11:00 AM ET. Nasus Pharma Ltd. (NYSE American: NSRX) presents at the Life Sciences Virtual Investor Forum, co-hosted by Virtual Investor Conferences and Zacks Small Cap Research, at 11:00 AM ET on Thursday, June 25, 2026, in a session moderated by John Vandermosten, CFA, Senior Analyst at Zacks Small Cap Research. The Life Sciences Virtual Investor Forum is a B2i Digital Featured Conference. For more details, please visit: https://b2idigital.com/vic-june-25th-life-sciences-virtual-investor-forum To register and view the presentation: https://www.virtualinvestorconferences.com/wcc/eh/4814904/lp/5397572/nasus-pharma-ltd-nyse-american-nsrx?utm_source=b2i&utm_medium=marketing&utm_campaign=0624LifeSciencesForumVIC Request a one-on-one meeting: https://app.axleaccess.com/public/events/636943bb-55cb-4a39-81b5-f658175de392?token=7b91921e-7b44-4da7-be93-ea5c37a5ed76 Dan Teleman, CEO, presents for Nasus Pharma alongside SVP and CFO Eyal Rubin. Teleman joined in January 2025 with over 20 years in the pharmaceutical industry, most recently as CEO of Pharma Two B and previously CEO of Atox Bio for 12 years, and holds an MBA from Duke University's Fuqua School of Business. Rubin brings more than 20 years of finance and capital markets experience, including CFO roles at Protalix BioTherapeutics and BrainStorm Cell Therapeutics. Nasus Pharma is a clinical-stage biopharmaceutical company developing innovative intranasal drug delivery products. Uniquely positioned to address medical emergencies, its proprietary Nasax technology is designed to enhance intranasal drug absorption with potential for longer product shelf life through a unique powder formulation. Learn more at https://ir.nasuspharma.com/. Virtual Investor Conferences is an OTC Markets Group Inc. property. Learn more at www.virtualinvestorconferences.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. B2i Digital is the Official Marketing Partner of Virtual Investor Conferences. Content is informational only and is not investment advice. B2i Digital is not a broker-dealer or investment adviser.
View on StockTwits ↗$NSRX NS002 June KOL Event https://buff.ly/k5rnB6i
View on StockTwits ↗$NSRX CEO purchased 6,550 shares at $3.10 for a total of $20,305. Teleman Dan Benjamin now owns 163,541 shares. https://ceo-buys.com
View on StockTwits ↗$NSRX This stock should go higher based on phase 3 study witch will start in September and will end before year end 2026 in December . I see 9-10$ in October and 20$ in December after FDA approval. Hold tight smart investors .
View on StockTwits ↗$NSRX is reporting positive preclinical pharmacokinetic and safety results for its intranasal ondansetron candidate NS003.
View on StockTwits ↗Among micro-cap biotech names, $NSRX has been attracting growing attention. The company's lead candidate, NS002, is a needle-free intranasal epinephrine powder designed for the $2B+ anaphylaxis treatment market, offering a potential alternative to traditional injectable products. Reported Phase 2 results showed: • Median time to therapeutic levels: 1.69 minutes • EpiPen comparison: 3.42 minutes • 91% reached therapeutic concentration within 5 minutes • No serious adverse events reported Beyond NS002, the company is advancing multiple pipeline candidates. Key milestones investors are watching include: • IND submission expected in Q3 2026 • Pivotal study planned for Q4 2026 • Potential data readout around Q1 2027 The company also completed a $15M private financing earlier this year to support clinical development. With a market capitalization of roughly $60M, future valuation changes will likely depend on clinical execution, regulatory progress, and upcoming trial results.
View on StockTwits ↗$NSRX 👀 Interesting micro-cap biotech setup. ✅ Higher lows forming ✅ Triangle breakout developing ✅ OBV improving ✅ TTM downside momentum fading ✅ Buyers defending the $2 area Meanwhile: • Positive NS002 Phase 2 data • Proprietary intranasal platform • $15M cash raise extending runway into 2027 Only ~$28M market cap. A clean break over $3.50-$4.00 could change the entire chart structure. Worth watching. 👀 $NSRX #biotech #stocks #trading Disclaimer: https://stockresearchtoday.com/nsrx/
View on StockTwits ↗$NSRX Breakout is happening. Now look at the structure: Float: 4.86M shares Insiders own: 49.11% Institutions own: 18.57% That's a very small tradable float. The chart is pressing against resistance while building higher lows. Market Cap: ~$27M When tiny floats start attracting momentum, things can move much faster than most expect. Source: https://finance.yahoo.com/quote/NSRX/key-statistics/ Disclaimer: https://stockresearchtoday.com/nsrx/
View on StockTwits ↗$NSRX Healthcare/Biotech land has been weak lately. That's exactly why this chart is interesting. While many names continue drifting lower, $NSRX is building higher lows and compressing into a tightening triangle near resistance. ✅ Buyers defending the $3 area ✅ RSI improving ✅ OBV recovering ✅ Volume slowly returning The key level remains $3.40-$3.50. Relative strength often shows up before the crowd notices. Disclaimer: https://stockresearchtoday.com/nsrx/
View on StockTwits ↗$NSRX Another interesting development that hasn't received much attention yet: Nasus Pharma is hosting a virtual KOL event on June 10, 2026, at 8:00 AM, highlighting NS002 and the company’s intranasal platform. Why does that matter? Because successful biotech stories are often built through: • Clinical execution • Scientific validation • Investor awareness The company continues checking those boxes. For a ~$27M market cap biotech advancing toward Phase 3, this is another catalyst worth monitoring closely. Source: https://finviz.com/news/358444/nasus-pharma-to-host-virtual-kol-event-on-june-10-2026-to-discuss-ns002-for-the-treatment-of-anaphylaxis Disclaimer: https://stockresearchtoday.com/nsrx/
View on StockTwits ↗$NSRX Bullish triangle finally resolving higher. ✅ Higher lows ✅ Volume returning ✅ OBV improving ✅ RSI recovering ✅ Sellers losing control The key level was $3.40-$3.50. Now the chart is starting to push through it. For a ~$27M market cap biotech, this setup could get interesting fast. Disclaimer: https://stockresearchtoday.com/nsrx/ #biotech #stocks
View on StockTwits ↗$NSRX https://www.globenewswire.com/news-release/2026/06/01/3304316/0/en/Nasus-Pharma-to-Host-Virtual-KOL-Event-on-June-10-2026-to-Discuss-
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.